Novo Nordisk shares escalating amid promising results for obese birth control pills Pharmaceutical
The value of the Novo Nordisk increased by more than 6.5 billion pounds after research showed that the new anti -foundation pill resulted in almost weight loss, such as its escape escape, as it raced against its American opponent Eli Lilly to obtain a tablet to the market.
The shares in the Danish company increased by more than 4.5 % on Thursday morning, in the hope that it would be able to do so from the market share to Eli Lily and the cheapest GLP-1. The shares decreased by almost 60 % last year with a slowdown in sales.
Novo Nordsek said on Thursday The daily pill version of Wegovy achieved the loss of “great weight” in a clinical trial, with nearly one of every three participants losing 20 % or more. The side effects were similar to the injection version.
This is the first oral GLP-1 drug submitted to the American organizer, Food and Drug Administration (FDA), and the company expects a decision on whether the Food and Drug Administration will agree to use it by the end of the year. Production has already begun on American Novo Nordisk sites.
The Danish company is heading to face with ELI Lilly daily weight loss pills, called Orforglipron. On Tuesday, the American drug maker said that one in five people lost 20 % or more over 72 weeks, in a trial of 3127 adults. Patients lost 12.4 % of the average body weight at the highest dose.
ELI Orforglipron has developed with a boat obtained from Chigai Pharmaceutical in Japan in 2018. ELI Lilly plans to provide birth control pills to the organizer for approval later this year, and some analysts say it can be followed quickly by the FDA. Analysts estimated the peak sales of $ 10 billion annually for Orforglipron, where Jefferies saw capabilities of up to $ 25 billion.
Matthew Weston, an UBS analyst, said he saw a “clear driving” for oral obesity in Novo, “although OrforiPron is still a threat to being a more developmental product, so a reduced price also. Fasting also does not require 30 minutes, so it can be considered a more convenient option.”
Although anti-obese strikes, which mimic the intestinal hormone called GLP-1, were very popular, they are very expensive, especially after increasing the recent Eli Lili prices of up to 170 % in the UK. NHS has reduced people with high clinical needs.
It is easy to manufacture, store, distribute, and manage birth pill versions, and it is expected to be cheaper, which paves the way for other millions of weight loss at a time when obesity is increasing all over the world.
The shares of GLP-1 pharmaceuticals dramatically outperformed the pharmaceutical companies that do not make these drugs lose weight. The Etoro Investment platform said on Tuesday that the shares of Novo Nordisk, Eli Lilly, Sanofi, TEVA and Hikma have increased by 106 % over the past five years, while Johnson & Johnson, GSK, Abbvie and Bayer Rose basket 27 %. ELI Lilly shares increased by approximately 395 % during this period while Novo Nordisk is still 69 %, although its sharp decrease last year.